157 filings
8-K
BPMC
Blueprint Medicines Corp
22 Feb 24
Other Events
8:20am
8-K
BPMC
Blueprint Medicines Corp
15 Feb 24
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
7:05am
8-K
BPMC
Blueprint Medicines Corp
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
8-K
BPMC
Blueprint Medicines Corp
26 Oct 23
Blueprint Medicines Reports Third Quarter 2023 Results
7:00am
8-K
BPMC
Blueprint Medicines Corp
25 Aug 23
Other Events
8:15am
8-K
98erh9kfrb 4gk7c3y
2 Aug 23
Blueprint Medicines Reports Second Quarter 2023 Results
7:00am
8-K
buqi5phm
30 Jun 23
Other Events
6:03am
8-K
kvq4i fgj
27 Jun 23
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
xhy34ytosj3zi c4f
25 May 23
Entry into a Material Definitive Agreement
4:32pm
8-K
10yhx
22 May 23
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
4:53pm
8-K
rwoe7s4q
4 May 23
Blueprint Medicines Reports First Quarter 2023 Results
7:18am
8-K
nmsvmhb
28 Mar 23
Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222
5:04pm
8-K
37d2ba
27 Feb 23
Regulation FD Disclosure
8:55am
8-K
r08o9hducdalqndm
23 Feb 23
Termination of a Material Definitive Agreement
4:06pm
8-K
1ykkiyhlumf
16 Feb 23
Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results
8:21am
8-K
dw7app8g
10 Feb 23
Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222
8:26am
8-K
aap04
9 Jan 23
Regulation FD Disclosure
8:30am
8-K
vfzg3
6 Jan 23
Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors
4:33pm
8-K
nhnjj
27 Dec 22
Departure of Directors or Certain Officers
4:27pm
8-K
kkvnonaj817s8vlp
6 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:12pm